Broad A F, Godlee J N, Emery E W, Prankerd T A
Postgrad Med J. 1968 Oct;44(516):803-6. doi: 10.1136/pgmj.44.516.803.
Thirty-six out of sixty-two cases of myelomatosis have been treated with melphalan. Platelet counts were used as a guide to dosage early in the course of treatment, after which a more empirical dosage (0·15 mg/kg/day) was used in 1-week courses given every 12 weeks. Rapid deterioration and death occur in a small number of patients whatever therapy is given. In the group treated with melphalan the median survival time was 25 months, longer than in those treated with radiotherapy or other chemotherapeutic agents.
62例骨髓瘤患者中有36例接受了美法仑治疗。在治疗初期，以血小板计数作为剂量指导，之后每12周进行为期1周的疗程，采用更凭经验的剂量（0.15毫克/千克/天）。无论采用何种治疗方法，少数患者都会迅速恶化并死亡。在接受美法仑治疗的组中，中位生存时间为25个月，比接受放疗或其他化疗药物治疗的患者更长。
